The United Laboratories International Holdings Limited announced that its wholly-owned subsidiary, Zhuhai United Laboratories Co., Ltd., has received approval from the U.S. Food and Drug Administration (FDA) for its investigational new drug $(IND)$ application for TUL108 for injection. TUL108 is a novel, broad-spectrum β-lactamase inhibitor developed by the company, intended for the treatment of infections caused by Gram-negative or Gram-positive bacteria, including complicated urinary tract infections, complicated intra-abdominal infections, pulmonary infections, and bloodstream infections. The IND approval allows the company to proceed with clinical development of TUL108 in the United States.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TUL - The United Laboratories International Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260128-12003715), on January 28, 2026, and is solely responsible for the information contained therein.